NCT00819910View on ClinicalTrials.gov

Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL)

PHASE4TerminatedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 30, 2008

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2010

Conditions
Hypertriglyceridemia in Type 4 HyperlipidemiaNon Diabetic Subjects With Normoglycemia
Interventions
DRUG

Rosiglitazone

Rosiglitazone 8mg daily for 12 weeks

DRUG

Placebo (Rosiglitazone)

Placebo (Rosiglitazone) 8mg daily for 12 weeks

DRUG

Placebo (Fenofibrate)

Placebo (Fenofibrate) 145 mg daily for 12 weeks

DRUG

Fenofibrate

Fenofibrate 145 mg daily for 12 weeks

Trial Locations (1)

78234

Brooke Army Medical Center, San Antonio

Sponsors

Collaborators (1)

GlaxoSmithKline
All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Ahmad Slim

FED

NCT00819910 - Rosiglitazone And Fenofibrate Additive Effects on Lipids (RAFAEL) | Biotech Hunter | Biotech Hunter